Piotr Adamowicz / Shutterstock.com
15 August 2016Americas

US court says epilepsy patent is valid

The US District Court for the District of Delaware has ruled that pharmaceutical company UCB’s patent covering epilepsy drug Vimpat (lacosamide) is valid, after it was challenged by generic drug makers.

The case centres on US patent number RE38, 551, which is due to expire in 2022.

UCB had sued various generic drug companies, including Argentum, in 2013 after they applied to produce a generic version of Vimpat.

The decision is currently under seal and will be released following an order from the court.

In a statement yesterday, August 14, Anna Richo, executive vice president of UCB, said it was pleased with the decision.

She added : “This confirms the strength of our intellectual property for Vimpat.”

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk